Passage Bio
IPO News: Filed S-1: Passage Bio Files $125mm IPO
Passage Bio

Passage Bio

NASDAQ:  PASG

Size (mm):  $125.0

Bookrunners:  J.P. Morgan | Goldman Sachs | Cowen

Co-Manager: Chardan

Major Holders:  OrbiMed | Versant Ventures | Frazier Life Sciences | LAV Prescience Limited | New Leaf Ventures | Vivo Capital | James Wilson (Scientific Founder) | AI Passage

Description:  Passage Bio is a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system, or CNS, disorders with limited or no approved treatment options.

Note:  Emerging Growth Company

 

Reference Link:  S-1